Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Alamar Biosciences, Inc.NASDAQ: ALMR
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income of -$13.2M in Q2 FY2026
Q2 FY2026 net income was -$13.2M.
Context
- Net income amounted to 40.2% of revenue in FY2025.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$93.26M (+212.8%) for the fiscal year ending Dec 2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$13.2M-38.1% QoQ
- Last fiscal yearDec 2025
- -$29.82M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +212.8% | — |
| 3-year CAGR | — | -0.4% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (29.82M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.82M) | — |
Net Income vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 net income of $29.82M is the smallest of the 9 companies compared; the peer median is $72.81M.
- Net income amounts to 40.2% of revenue for ALMR, versus a peer median of 80.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $171.97M | +120.5% | -14.0% | 14.0% | |
| LTM Sep 2026 | $130.2M | +67.6% | -14.0% | 28.3% | |
| LTM Mar 2026 | $128.58M | -80.5% | +20.2% | 80.3% | |
| LTM Mar 2026 | $103.82M | +3.1% | -8.5% | 5605.9% | |
| LTM Mar 2026 | $78.21M | +158.9% | -26.7% | 90.7% | |
| LTM Jun 2026 | $75.13M | -11.2% | -36.0% | 12.2% | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
ALMRAlamar Biosciences, Inc. | FY2025 | $29.82M | — | — | 40.2% |
| Peer median (excluding ALMR) | $72.81M | -4.1% | -11.2% | 80.3% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (29.82M) |
| Depreciation & Amortization | 3.86M |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.87M |
| Change in Working Capital | (32.57M) |
| Accounts Receivables | (5.5M) |
| Inventory | (23.78M) |
| Accounts Payables | (572K) |
| Other Working Capital | (2.72M) |
| Other Non-Cash Items | 2.05M |
| Operating Cash Flow | (53.61M) |
| Capital Expenditures | (6.38M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (4.94M) |
| Sales of Investments | 57.5M |
| Other Investing Activities | (1.01M) |
| Investing Cash Flow | 46.18M |
| Debt Repayment | 10M |
| Common Stock Issued | 1.49M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (657K) |
| Financing Cash Flow | 10.84M |
| Effect of Forex Changes | (172K) |
| Net Change in Cash | 3.23M |
| Free Cash Flow | (59.99M) |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.